In an article published in JAMA, George Lowenstein of Carnegie Mellon University and Ian Larkin of the University of California, Los Angeles, outline the problems associated with the fee-for-service arrangements under which most doctors currently operate.

Among more than 200 new pharmaceuticals and biologics approved by the FDA from 2001 through 2010, nearly one-third were affected by a post-marketing “safety event,” such as the issuance of a boxed warning or safety communication, according to a new study published in JAMA.

The burgeoning cost of buying health insurance on the ACA exchanges continues as health insurers in the first states to make public filings—Maryland, Virginia, and Connecticut—want to increase premiums by at least 20%, according to Bloomberg News.

High-risk pools are poised to make a comeback, as they are an important element in the GOP’s American Health Care Plan, which would replace the ACA.

Express Scripts, the country’s biggest PBM, yesterday unveiled a program that it claims will make drugs more accessible to a portion of the population that currently cannot afford medications. The program is called InsideRX and consumers can sign up for free, the New York Times reports.

Speaking at the American Hospital Association’s annual membership meeting, FBI Director James Comey said that one of the key approaches the bureau is taking to improve its responses to cyber security threats is to build stronger relationships with “private community entities,” according to an article posted on the FierceHealthcare website.

The FDA has approved edaravone (Radicava, Mitsubishi Tanabe Pharma America, Inc.) for the treatment of patients with amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease. In the United States, the only other approved ALS medication, generic riluzole, modestly slows disease progression in some patients.

The FDA has issued a complete response letter (CRL) regarding the new drug application (NDA) for TX-004HR (TherapeuticsMD, Inc.), an investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy due to menopause.

Republican senators plan to write a health care bill that could be radically different from the one passed last week by the House, according to a Bloomberg report.

Under the health care bill passed by the House, it’s up to states to decide whether they want to dismantle key parts of the Patient Protection and Affordable Care Act (PPACA). GOP-leaning states are sure to be interested in rolling back the act’s coverage requirements and in freeing insurers to charge people more when they have pre-existing conditions.

When the just-passed House measure to overhaul the Patient Protection and Affordable Care Act (PPACA) reaches the Senate, the bill is expected to undergo sweeping changes that might leave it unrecognizable—perhaps stripping away some of the provisions that helped earn the support of far-right House members, according to an article in The New

After weeks of will-they-or-won’t-they tensions, the House finally passed its GOP replacement for the Patient Protection and Affordable Care Act (PPACA) by a vote of 217 to 213. Now the bill moves across the Capitol to the Senate—and the job doesn’t get any easier.

Much is known about flu viruses, but little is understood about how they reproduce inside human host cells, spreading infection.

An international group of experts has concluded that, for patients with schizophrenia and related psychotic disorders, antipsychotic medications do not have negative long-term effects on patients' outcomes or the brain. In addition, the benefits of these medications are much greater than their potential side effects.

A team of researchers from the University of Freiburg and the University Medical Center Freiburg in Germany and the Kinghorn Cancer Center/Garvan Insitute in Australia has identified a potential new target for cancer therapy.